LI PAN1, WENTING YI2, DONGMIN LIANG1, YULONG ZHAO1, RANRAN WANG1, PINGYU WANG1, YOUJIE LI1, JIAXUAN XIN1, YUNFEI YAN1,*,#, SHUYANG XIE1,*,#
BIOCELL, Vol.46, No.2, pp. 417-431, 2022, DOI:10.32604/biocell.2022.015522
- 20 October 2021
Abstract Tumor progression is usually characterized by proliferation, migration, and angiogenesis, which is essential for
supplying both nutrients and oxygen to the tumor cells. Therefore, targeting angiogenesis has been considered a
promising therapeutic strategy for cancer prevention and treatment. In the present study, we demonstrated that in
addition to suppressing lung cancer cell proliferation and migration in vitro, 10-hydroxycamptothecin (10-HCPT) is
also capable of inhibiting angiogenesis in vivo with a miR-181a-dependent manner. Mechanistically, by upregulating
miR-181a, which in turn downregulating FOXP1, 10-HCPT can inhibit the PI3K/Akt/ERK signaling pathwaymediated angiogenesis. Furthermore, reduced levels of miR-181a have been found in More >